Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 2/20 | 0.32 |
| ▸ | FEN1 | P39748 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21722877 | 0.82 | BACE1 (0.30) | BACE1 | |
| SCHEMBL20972155 | 0.79 | BACE1 (0.30) | BACE1 | |
| SCHEMBL29274170 | 0.77 | BACE1 (0.33) | BACE1 | |
| SCHEMBL23831751 | 0.77 | IDO1 (0.41) | ALOX5APFEN1BACE1 | |
| SCHEMBL2120520 | 0.76 | BACE1 (0.33) | ALOX5APFEN1BACE1 | |
| SCHEMBL2596488 | 0.75 | DPP4 (0.33) | BACE1 | |
| SCHEMBL31547080 | 0.75 | APLNR (0.32) | BACE1 | |
| SCHEMBL21722860 | 0.74 | BACE1 (0.35) | BACE1 | |
| SCHEMBL22801148 | 0.72 | TDP1 (0.38) | BACE1 | |
| SCHEMBL14659892 | 0.72 | AOC1 (0.37) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12358906-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | NOVARTIS AG (CH) | 2025-07-15 | — | — | US | disclosed |
| CN-118666832-A | Urea compounds and compositions as SMARCA2/BRM atpase inhibitors | 诺华股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20240270738-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | NOVARTIS AG (CH) | 2024-08-15 | — | — | US | disclosed |
| CN-112585136-B | Urea compounds and compositions as SMARCA2/BRM atpase inhibitors | 诺华股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11958846-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | NOVARTIS AG (CH) | 2024-04-16 | — | — | US | disclosed |
| EP-4219488-A1 | METHOD FOR THE PREPARATION OF UREA COMPOUNDS AS SMARCA2/BRM-ATPASE INHIBITORS | Novartis AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| EP-3837256-B1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM-ATPASE INHIBITORS | NOVARTIS AG (CH) | 2023-03-08 | — | — | EP | disclosed |
| US-20210323956-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | NOVARTIS AG (CH) | 2021-10-21 | — | — | US | disclosed |
| EP-3837256-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | Novartis AG (CH) | 2021-06-23 | — | — | EP | disclosed |
| CN-112585136-A | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | 诺华股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2020251971-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020251971-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020035779-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | NOVARTIS AG (CH) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958846-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | SMARCC1, SMARCC2, SMARCA1 | ALOX5AP 4805/4885FEN1 1308/4885BACE1 2863/4885 |
| US-20210323956-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | SMARCC1, SMARCC2, SMARCA1 | ALOX5AP 4805/4885FEN1 1308/4885BACE1 2863/4885 |
| US-12358906-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | SMARCC1, SMARCC2, SMARCA1 | ALOX5AP 4861/4885FEN1 1141/4885BACE1 3365/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | ALOX5AP 4836/4885FEN1 1745/4885BACE1 1701/4885 |
| US-20240270738-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | SMARCC1, SMARCC2, SMARCA1 | ALOX5AP 4859/4885FEN1 1055/4885BACE1 3188/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | ALOX5AP 4344/4885FEN1 922/4885BACE1 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.